Barinthus Biotherapeutics PLC (BRNS) intrinsic value & 10-year financials
Barinthus Biotherapeutics PLC (BRNS) has a Graham intrinsic value of $4.65 per share. Over the last 7 fiscal years revenue grew 32.7% a year to $0, with an average return on invested capital of -58.5%.
- Graham intrinsic value
- $4.65
- Revenue (FY2025)
- $0
- Revenue growth (7-yr CAGR)
- 32.7%
- ROIC (10-yr avg)
- -58.5%
- Free cash flow (FY2025)
- -$48.0M
BRNS 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $0 | -$66.4M | -$1.64 | -$48.0M | — | -331.4% |
| FY2024 | $15.0M | -$61.1M | -$1.55 | -$29.8M | -454.1% | -159.2% |
| FY2023 | $802.0K | -$73.3M | -$1.91 | -$56.3M | -10463.1% | -142.9% |
| FY2022 | $44.7M | $5.3M | $0.14 | -$20.6M | -9.0% | -8.0% |
| FY2021 | $268.0K | -$50.9M | -$1.96 | -$33.7M | -16873.5% | 265.1% |
| FY2020 | $4.8M | -$17.7M | -$2.24 | -$11.3M | -415.8% | 25.5% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Barinthus Biotherapeutics plc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Barinthus Biotherapeutics plc. has historically struggled to out-earn its cost of capital, averaging just -21.3% ROIC.
Barinthus Biotherapeutics plc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Barinthus Biotherapeutics plc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $4.65 per share.